• If you are wondering whether Johnson & Johnson stock still offers value after a strong run, this article breaks down what the current price might be implying about the business.
• The stock last closed at US$254.66, with returns of 11.5% over 7 days, 10.1% over 30 days, 22.8% year to date and 71.3% over 1 year. This performance has put valuation firmly in focus for many investors.
• Recent headlines around Johnson & Johnson have kept attention on the stock, including ongoing discussion of its pharmaceutical pipeline and consumer health positioning. These themes help frame how investors are thinking about future cash flows and risk around the current share price.
• On Simply Wall St's valuation checks, Johnson & Johnson scores 2 out of 6. The next sections will walk through what different valuation approaches suggest about the stock and finish with a broader way to think about value beyond just the headline numbers.

Johnson & Johnson scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Johnson & Johnson stock might be worth by projecting future cash flows and discounting them back to today using a required return. It focuses on the cash the company could generate for shareholders over time.

For Johnson & Johnson, the latest twelve month Free Cash Flow is about $17.0b. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolated estimates project Free Cash Flow reaching about $35.9b in 2030, with a path of forecast and modeled values between 2026 and 2035. Simply Wall St uses analyst inputs where available and then extends the series with its own assumptions for the later years.

Based on these cash flow projections, the model arrives at an estimated intrinsic value of $374.05 per share. Compared with the recent share price of $254.66, this DCF output points to an implied discount of 31.9%, which indicates the stock appears undervalued on this measure.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 31.9%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Johnson & Johnson Price vs Earnings

For profitable companies like Johnson & Johnson, the P/E ratio is a common way to think about value because it links what you pay for the stock to the earnings the business is currently generating. In general, higher growth expectations or lower perceived risk can support a higher P/E, while slower expected growth or higher risk usually line up with a lower, more conservative multiple.

Johnson & Johnson currently trades on a P/E of 29.14x. This sits above the Pharmaceuticals industry average of 15.12x and slightly above the peer group average of 28.21x. Simply Wall St also calculates a proprietary “Fair Ratio” for the stock of 26.64x. This Fair Ratio is an estimate of what might be a more suitable P/E given factors such as earnings growth, profit margins, industry, market cap and company specific risks.

Because the Fair Ratio incorporates these company specific drivers, it can be more informative than a simple comparison with industry or peer averages, which may not share the same risk and growth profile. Comparing Johnson & Johnson’s current P/E of 29.14x with the Fair Ratio of 26.64x suggests the stock looks overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St take your view of Johnson & Johnson, link that story to a set of revenue, earnings and margin assumptions, turn those into a Fair Value, then continuously refresh that view when news or earnings arrive, so you can compare Fair Value with the live share price and decide whether the stock looks attractive or not based on your own judgment.

On the Johnson & Johnson Community page, for example, one investor Narrative currently anchors on a Fair Value of about US$181.77 while another sits closer to US$265.00. Both are valid because each reflects a different story about how oncology, MedTech, margins and risks might play out over time, giving you a clear way to see where your own expectations sit on that spectrum before you act.

For Johnson & Johnson, however, we will make it really easy for you with previews of two leading Johnson & Johnson Narratives:

Fair Value: US$265.00 per share

Implied discount to this Fair Value at US$254.66: about 3.9%

Revenue growth assumption: 7.10%

• Backs a broad set of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision products, with 28 platforms already generating at least US$1b in annual revenue.
• Uses a more optimistic analyst view that assumes revenue growth of 7.10% a year, earnings of US$26.2b by 2029 and a higher future P/E of 29.9x, discounted at about 7.0%.
• Highlights concentration in blockbuster products, pricing pressure, higher structural costs, acquisition risk and legal exposure as key factors that could challenge this optimistic story.

Fair Value: US$252.87 per share

Implied premium to this Fair Value at US$254.66: about 0.7%

Revenue growth assumption: 6.56%

• Leans on a consensus view that Johnson & Johnson grows revenue by 6.56% a year with profit margins rising from 21.8% to 23.1% and earnings reaching US$26.9b by 2029.
• Assumes a 27.7x P/E on those 2029 earnings and a 7.11% discount rate while recognising that analyst targets span a wide range between US$155.00 and US$285.00.
• Flags loss of exclusivity for key drugs, tariffs, ongoing talc litigation, pressure in Orthopaedics and acquisition related dilution as central risks that could limit upside.

These two narratives frame how different investors are thinking about Johnson & Johnson at today’s share price and give you a starting point to decide which set of assumptions, if either, lines up more closely with your own view of the stock.

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.